Back to search results

ARTEMIS: Ziltivekimab for Heart Attack Recovery

This study, called ARTEMIS, is looking at whether ziltivekimab can help people who have recently had a heart attack. Ziltivekimab is a new medicine that is not yet approved. The goal is to see if it can reduce the chances of having another heart attack or stroke. You would receive either ziltivekimab or a placebo (a dummy medicine) through a monthly injection under your skin. The study will follow participants for up to 25 months to see if ziltivekimab prevents serious heart problems like another heart attack, stroke, or death related to heart issues. To join, you must be at least 18 years old and have been hospitalized for a specific type of heart attack.

Study design
This is an interventional study where participants are randomly assigned to receive either ziltivekimab or a placebo. It plans to enroll 10,000 participants.
What's involved
You would need to inject the study medicine into your stomach, thigh, or upper arm once every month. The study will last for about 2 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from randomization up to 25 months to track major adverse cardiovascular events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06118281

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatment
Novo Nordisk A/S
~10,000 participants
Updated 2026-09-09 on ClinicalTrials.gov
What's tested:ZiltivekimabPlacebo

At a glance

Recruiting sites
0 of 836 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal stroke
Measured over From randomisation (month 0) to end-of-study (up to 25 months)

Conditions

Cardiovascular Risk
Acute Myocardial Infarction (AMI)

Explore related trials

Acute Myocardial InfarctionCardiovascular Risk

NCT06118281

Where you'd take part

This study runs at 836 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • 'G. Gennimatas' General Hospital of Athens

    Athens, Greeceno site contact published

  • 'G. Gennimatas' General Hospital of Athens - Cardiology Department

    Athens, Greeceno site contact published

  • "AHEPA" University General Hospital of Thessaloniki

    Thessaloniki, Greeceno site contact published

  • "Hygeia" General Hospital of Athens

    Athens, Greeceno site contact published

  • "Sotiria" Thoracic Diseases Hospital of Athens

    Athens, Greeceno site contact published

  • "UMHAT "Sveta Anna" Sofia" AD, Clinic of Cardiology

    Sofia, Bulgariano site contact published

  • 1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ

    Lublin, Polandno site contact published

  • 10 Wojskowy Szpital Kliniczny z Poliklinika - Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Bydgoszczy

    Bydgoszcz, Polandno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Clinical Transparency dept. 2834 · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal strokeFrom randomisation (month 0) to end-of-study (up to 25 months)

    Measured in months.